SECOND QUARTER IN BRIEF Start of enrollment to the clinical phase I biodistribution study with laquinimod eye drops (April 3) Active Biotech acquired exclusive rights to patents of tasquinimod in combination therapy in multiple myeloma (May 22) Clinical activity and safety of naptumomab and docetaxel in non-small cell lung cancer…
Lund, July 15 2024 – Active Biotech (NASDAQ STOCKHOLM: ACTI) today announced an update to a clinical study of tasquinimod in patients with relapsed refractory multiple myeloma (RRMM) being conducted at the Abramson Cancer Center at the University of Pennsylvania in Philadelphia. The study is ongoing in its expansion cohort…
Lund, July 1, 2024 – Active Biotech (NASDAQ STOCKHOLM: ACTI) today announced it has entered into a clinical study agreement for a Phase II investigator-initiated clinical study investigating the use of tasquinimod in myelofibrosis. The study will be led by Lucia Masarova, M.D., assistant professor of Leukemia at The University…
The number of shares and votes in Active Biotech has changed as a result of allotment of performance shares under the company’s incentive program for the company’s employees (Plan 2020/2024). Today, the last trading day of the month, there are in total 361,813,142 shares and votes in Active Biotech. For…
Lund, May 28, 2024 – Active Biotech (NASDAQ STOCKHOLM: ACTI) announces today that NeoTX Therapeutics, exclusive licensee of naptumomab estafenatox (naptumomab, NAP) from Active Biotech, will present initial results from phase IIa trial with NAP and docetaxel in advanced/metastatic Non-Small Cell Lung Cancer (NSCLC) patients, at the American Society of…
The Annual General Meeting of Active Biotech was held on May 22, 2024. The following main resolutions were passed.In accordance with the Board of Directors’ proposal, it was resolved that no dividend would be paid for the financial year 2023, and that the Company’s accumulated loss shall be carried forward.…
Lund, May 22, 2024 – Active Biotech (NASDAQ STOCKHOLM: ACTI) today announces it has entered into an exclusive license agreement with the Wistar Institute of Anatomy and Biology (“Wistar”), Philadelphia, US for the global rights to Wistars interest in the joint IP relating to the use of tasquinimod in combination…
FIRST QUARTER IN BRIEF Preparations ongoing for start of the clinical proof of concept studies with tasquinimod in myelofibrosis The expansion cohort of the study in multiple myeloma is ongoing according to plan EVENTS AFTER THE END OF THE PERIOD Start of enrollment to the clinical phase I biodistribution study…
The shareholders of Active Biotech AB (publ), Reg. No. 556223-9227, with its registered office in Lund, Sweden, are invited to the Annual General Meeting of shareholders to be held on Wednesday, May 22, 2024 at 5 p.m. CEST in the premises of the Company at Scheelevägen 22, SE-223 63 Lund,…
Active Biotech (NASDAQ Stockholm:ACTI) announces today that the Annual Report 2023 now is available for download at www.activebiotech.com. The Annual Report will only be digitally distributed. “I am very pleased with the progress of our projects in 2023. We are strengthened in our belief that our projects have the potential to…
Lund, April 3, 2024 – Active Biotech (NASDAQ STOCKHOLM: ACTI) today announced that the clinical phase I biodistribution study Safety, Tolerability, and Distribution of Laquinimod Eye Drops: The LION Study (clinicaltrials.gov NCT06161415) with laquinimod eye drops is now recruiting patients following the approval from the Food and Drug Administration (FDA)…
FOURTH QUARTER IN BRIEF Lead Principal Investigator Rebekka Schneider-Kramann presents the clinical plan and positioning of tasquinimod in myelofibrosis (December 1) Active Biotech enters into collaboration agreement for clinical ocular biodistribution study with laquinimod (December 5) Active Biotech announces outcome of the Company’s rights issue (December 6) Preclinical data of…
The number of shares and votes in Active Biotech AB (publ) has changed as a result of the recently completed rights issue. Today, the last trading day of the month, there are in total 361,739,047 shares and votes in Active Biotech. For further information, please contact: Helén Tuvesson, CEO, +46 46…
Lund, December 22, 2023 – Active Biotech (NASDAQ STOCKHOLM: ACTI) today announced an update to the timelines of its scheduled clinical studies to be initiated in 2024, backed by the company’s recently completed successful financing round. The next step in the development of the drug candidate laquinimod will be a…
Lund, December 14, 2023 – Active Biotech (NASDAQ STOCKHOLM: ACTI) today announced that preclinical data on tasquinimod, a small molecule immunomodulator, in myelofibrosis and myelodysplastic syndrome (MDS) are now available on the company’s website. The data were presented at the 65th American Society of Hematology Annual Meeting (ASH 2023) in…
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, NEW ZEALAND, HONG KONG, JAPAN, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, RUSSIA, BELARUS OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE…
Lund, December 5, 2023 – Active Biotech (NASDAQ STOCKHOLM: ACTI) today announced that it has entered into a clinical trial collaboration agreement with the Global Ophthalmic Research Center (GORC), Los Altos, CA, US for a phase I clinical ocular biodistribution study with laquinimod eye drops. GORC is the study administrative…
In accordance with a decision made by the Annual General Meeting held on May 24, 2023, the Nomination Committee shall comprise the representatives for the three largest shareholders by votes, as per end of September 2023, and the Chairman of the Board. If a shareholder does not exercise its right…
Lund, December 1, 2023 – Active Biotech (NASDAQ STOCKHOLM: ACTI) announced today that a recorded presentation and an interview on the positioning of tasquinimod in the evolving landscape of myelofibrosis with Professor Rebekka Schneider-Kramann are available on the company website (www.activebiotech.com). Active Biotech has communicated earlier that it will focus…
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, NEW ZEALAND, HONG KONG, JAPAN, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, RUSSIA, BELARUS OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE…
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, NEW ZEALAND, HONG KONG, JAPAN, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, RUSSIA, BELARUS OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE…
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, NEW ZEALAND, HONG KONG, JAPAN, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, RUSSIA, BELARUS OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE…
THIRD QUARTER IN BRIEF Collaboration agreement for clinical study with tasquinimod in myelofibrosis signed (July 31) Tasquinimod successfully completed dose optimization in patients with multiple myeloma and advances into the pre-planned expansion cohort (September 11) Clinical safety and preclinical ocular biodistribution for laquinimod eye drops presented at the IOIS meeting…
Lund, November 2, 2023 – Active Biotech (NASDAQ STOCKHOLM: ACTI) announced today that two abstracts with preclinical data for tasquinimod in myelofibrosis and myelodysplastic syndrome have been accepted for presentation at the 65th American Society of Hematology Annual Meeting in San Diego, December 9-12, 2023 (ASH 2023). The abstract demonstrating…
Lund, September 13 2023 – Active Biotech (NASDAQ Stockholm:ACTI) announces today that data from the recently completed phase I study with the eye drop formulation of laquinimod, a small molecule immunomodulator in development for non-infectious uveitis, together with results from the intraocular biodistribution study of laquinimod eye drops in rabbit,…
Lund Sweden, September 11, 2023 – Active Biotech (NASDAQ STOCKHOLM: ACTI) today announces the successful completion of the dose escalation of tasquinimod in combination with the orally administered antimyeloma agents ixazomib, lenalidomide, and dexamethasone (IRd) in patients with relapsed or refractory multiple myeloma. 6 patients have been treated with increasing…
SECOND QUARTER IN BRIEF Safety and preliminary efficacy of naptumomab in combination with durvalumab presented at AACR 2023 (April 19) Positive interim data from the ongoing study of tasquinimod in heavily pre-treated patients with relapsed and refractory multiple myeloma presented at ASCO 2023 (May 26) Positive safety and tolerability in…
Lund, July 31 2023 – Active Biotech (NASDAQ STOCKHOLM: ACTI) today announced it has entered into a clinical trial collaboration agreement with Stichting Haemato-Oncologie Volwassenen Netherland (HOVON) and Stichting Oncode Institute (Oncode) for the upcoming clinical proof-of-concept trial of tasquinimod in myelofibrosis. HOVON will be the legal sponsor of the…
Lund, May 30 2023 – Active Biotech (NASDAQ Stockholm:ACTI) announces today that data from the recently completed phase I study with the eye drop formulation of laquinimod, a small molecule immunomodulator in development for ocular inflammation, will be presented in a poster session at the International Ocular Inflammation Society (IOIS)…
Lund, May 26 2023 – Active Biotech (NASDAQ Stockholm; ACTI) announces today that tasquinimod, when given as monotherapy or in combination with ixazomib, lenalidomide and dexamethasone (IRd), has a favourable safety profile in heavily pre-treated patients with a median of 8 previous lines. All 15 patients included in this interim…
The Annual General Meeting of Active Biotech was held on May 24, 2023. The following main resolutions were passed. In accordance with the Board of Directors’ proposal, it was resolved that no dividend would be paid for the financial year 2022, and that the Company’s accumulated loss shall be carried…
Lund, May 11 2023 – Active Biotech (NASDAQ Stockholm:ACTI) announces today that new data on the mechanisms by which tasquinimod ameliorates bone marrow fibrosis in a murine model of myelofibrosis will be presented in an oral session at the European Hematology Association Congress in Frankfurt, 8-11 June, 2023. Previous studies…
FIRST QUARTER IN BRIEF Active Biotech confirmed positive clinical safety profile of laquinimod eye drops (January 30) Active Biotech published new preclinical data highlighting the mechanisms behind the anti-tumor activity of tasquinimod in hematological malignances New preclinical data on naptumomab published EVENTS AFTER THE END OF THE PERIOD Safety and…
Lund, April 27 2023 – Active Biotech (NASDAQ Stockholm:ACTI) announces today that new data from the ongoing study with tasquinimod, a small molecule immunomodulator, in multiple myeloma will be presented in a poster session at the American Society of Clinical Oncology (ASCO) 2023 Annual Meeting in Chicago, 2-6 June, 2023.…
Active Biotech’s Annual Report 2022 is now available for download at www.activebiotech.com. The Annual Report will only be digitally distributed. For further information, please contact: Helén Tuvesson, CEO, +46 46 19 21 56, helen.tuvesson@activebiotech.comHans Kolam, CFO, +46 46 19 20 44, hans.kolam@activebiotech.com About Active Biotech Active Biotech AB (publ) (NASDAQ Stockholm: ACTI) is…
The shareholders of Active Biotech AB (publ), Reg. No. 556223-9227, with its registered office in Lund, Sweden, are invited to the Annual General Meeting of shareholders to be held on Wednesday, May 24, 2023 at 5 p.m. CEST in the premises of the Company at Scheelevägen 22, SE-223 63 Lund,…
Lund, April 19 2023 – Active Biotech (NASDAQ STOCKHOLM: ACTI) announces today that NeoTX Therapeutics, exclusive licensee of naptumomab estefanatox (naptumomab, Nap) from Active Biotech presented the following interim results from the phase Ib trial with naptumomab in combination with the checkpoint inhibitor durvalumab in patients with advanced or metastatic…
Lund, Sweden — April 11, 2023 – Active Biotech (NASDAQ STOCKHOLM: ACTI) today announced the acceptance of an abstract at the American Association for Cancer Research (AACR) 2023 Annual Meeting in Orlando, Florida, April 14-19, 2023. The poster will present the results of safety and preliminary activity in the phase…
The number of shares and votes in Active Biotech has changed as a result of allotment of performance shares under the company’s incentive program for the company’s employees (Plan 2020/2024). Today, the last trading day of the month, there are in total 265,144,687 shares and votes in Active Biotech. For…
FOURTH QUARTER IN BRIEF Active Biotech further strengthened the patent protection for laquinimod in eye disorders with a granted patent in US (Oct 24) Preclinical data with tasquinimod in MDS presented at ASH 2022 (Dec 13) Phase I Multiple dose study of laquinimod recruited final patient OTHER SIGNIFICANT EVENTS JAN…
Lund, January 30, 2023 – Active Biotech (NASDAQ STOCKHOLM: ACTI) today announced the completion of the phase I clinical study testing the safety and tolerability of the newly developed laquinimod eye drop formulation in healthy subjects. According to the results, the eye drop was safe and well tolerated both at…
Lund, December 13, 2022 – Active Biotech (NASDAQ STOCKHOLM: ACTI) today announced that preclinical data on tasquinimod, a small molecule immunomodulator, in myelodysplastic syndrome (MDS), are now available on the company’s website. The data were presented at a poster presentation at the 64th American Society of Hematology Annual Meeting in…
In accordance with a decision made by the Annual General Meeting held on May 19, 2022, the Nomination Committee shall comprise the representatives for the three largest shareholders by votes, as per end of September 2022, and the Chairman of the Board. If a shareholder does not exercise its right…
Lund, November 3, 2022 – Active Biotech (NASDAQ STOCKHOLM: ACTI) today announced that an abstract with preclinical data on tasquinimod, a small molecule immunomodulator, in myelodysplastic syndrome (MDS), has been accepted for presentation at the 64th American Society of Hematology Annual Meeting in New Orleans, Louisiana, December 10-13, 2022 (ASH…
THIRD QUARTER IN BRIEF Based on the authorization from the general meeting, the board of directors resolved to carry out a rights issue of approximately SEK 55 million to secure financing of the ongoing and planned development programs (Aug 4) The first part of the multiple dose of laquinimod eye…
Lund, October 24, 2022, Active Biotech (NASDAQ STOCKHOLM: ACTI) today announced that the US Patent Office (USPTO) has issued a decision to grant Active Biotech’s patent related to use of laquinimod as treatment of eye diseases associated with excessive vascularization. The patent will be issued on 25 October, 2022, under…
The number of shares and votes in Active Biotech AB (publ) has changed as a result of the recently completed rights issue. Today, the last trading day of the month, there are in total 264,886,797 shares and votes in Active Biotech. For further information, please contact: Helén Tuvesson, CEO, +46 46…
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, JAPAN OR CANADA OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR REQUIRE REGISTRATION OR ANY OTHER MEASURES BEYOND WHAT IS REQUIRED UNDER SWEDISH LAW Active…
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, JAPAN OR CANADA OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR REQUIRE REGISTRATION OR ANY OTHER MEASURES BEYOND WHAT IS REQUIRED UNDER SWEDISH LAW The…
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, JAPAN OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR REQUIRE REGISTRATION OR ANY OTHER MEASURES BEYOND WHAT IS REQUIRED UNDER SWEDISH LAW The board…
